Event Outline
The Cancer Drug Development Forum (CDDF) Annual Conference is a leading event bringing together key stakeholders in oncology drug development, including academic researchers, industry representatives, regulatory authorities, health technology assessment agencies and patient advocates. Held from 9 to 11 February 2026 in a hybrid format, the conference will facilitate high-level discussion and collaboration across sectors.
This year’s programme examined the global landscape of cancer drug development, with a focus on regional regulatory perspectives, trial representativeness and diversity, patient-reported outcomes, and the use of big data. The meeting aimed to foster shared understanding and drive innovation in research and treatment delivery.
Learning outcomes / Meeting objective
- Session 1: Provide an overview of regulatory approaches across global regions and discuss their implications for designing trials intended for international registration.
- Session 2: Examine the concept of representativeness in clinical trials, highlighting definitions, practical applications and current challenges.
- Session 3: Explore patient-relevant endpoints from patient, industry and regulatory viewpoints, emphasising their value and integration into clinical development.
- Session 4: Discuss the role of Big Data and federated datasets in supporting global clinical research and trial optimisation.
- Session 5: Present the latest findings and outputs from CDDF’s Diversity Initiative.
Target audience
The target is a multidisciplinary audience of academia representatives, EU and US regulatory bodies (EMA, FDA, National Agencies), the pharmaceutical industry, HTAs, and patient advocates.
Language
The main language of the workshop is English.